Search Clinical Trials in the EU

Duration

Visits

Safety phase (I)

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

601-620 of 936 trials

Pancreatic Cancer: Durvalumab and Rintatolimod Combination

We are studying a new treatment combining durvalumab and rintatolimod for patients with metastatic pancreatic ductal adenocarcinoma. The goal is to see if this combination is safe and improves survival and quality of life.

Metastatic Pancreatic Cancer6-12 monthsSafety phase (I)Efficacy phase (II)>20 visits No Placebo Investigational MedicinesGastroenterologyOncology

Immune Response Study: Posdinemab

We are examining how the immune system reacts in participants who received Posdinemab. This research aims to improve our understanding of its effects on the immune system.

Alzheimer's Disease>2 yearsSafety phase (I)Neurology

Leukemia: Venetoclax with Stem Cell Transplant

We are evaluating the safety and effectiveness of Venetoclax combined with standard treatment for patients with high-risk MDS, CMML, or sAML undergoing stem cell transplantation. This study aims to improve outcomes and reduce complications during treatment.

Leukemia>2 yearsSafety phase (I)Efficacy phase (II)≤5 visits No Placebo Standard MedicinesHematologyOncology

Advanced Solid Tumors: OMTX705 Treatment

We are testing a new antibody-drug conjugate for patients with advanced solid tumors. The study looks at its effects alone and in combination with another treatment to see how well it works.

Tumors Expressing Fibroblast Activation Protein (FAP)>2 yearsSafety phase (I)Oncology

Relapsed or Refractory Tumors: AcSé-ESMART Trial

We are studying new treatment options for children and adolescents with hard-to-treat tumors. The goal is to see if these treatments are safe and effective based on the specific characteristics of their tumors.

Pediatric Cancer>2 yearsSafety phase (I)Efficacy phase (II)No Placebo Investigational MedicinesOncologyPediatrics

Advanced Solid Tumors: OSE-279 Treatment Study

We are investigating a new monoclonal antibody, OSE-279, for patients with advanced solid tumors or lymphomas. The study aims to find the best dose and evaluate its safety and effectiveness compared to existing treatments.

Stage IV Non-Small Cell Lung CancerAdvanced Solid TumorsLymphoma1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOncology

Urinary Incontinence: Mesenchymal Stem Cells Study

We are exploring the use of mesenchymal stem cells for women over 50 with urinary incontinence. This study aims to determine if this treatment is safe and feasible for this age group.

Urinary Incontinence in Older WomenSafety phase (I)Gynecology and ObstetricsUrology

Evaluating Safety of COR-1389

We are studying a new medication called COR-1389 to see how safe it is and how well the body tolerates it. This research may help improve treatment options in the future.

Obesity1-2 yearsSafety phase (I)EndocrinologyNephrology

RES-010 for Overweight and Moderately Obese Adults

We are investigating a new medication to see how safe it is and how it affects the body in healthy adults who are overweight or moderately obese. This study aims to gather important information about its potential benefits.

Obesity1-2 yearsSafety phase (I)EndocrinologyInternal Medicine

MDS and AML: Venetoclax with Azacitidine

We are studying a new treatment combining venetoclax and azacitidine with donor lymphocyte infusion for patients with MDS or AML who have relapsed after a stem cell transplant. The goal is to assess its safety and effectiveness.

Acute Myeloid LeukemiaMyelodysplastic Syndromes>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Standard MedicinesHematologyOncology

Sarcomas: New Treatment Approach with DDR-Inhibition

We are exploring a new combined treatment for patients with sarcomas to see if it is safe and effective. This study aims to improve treatment options for those affected by this type of cancer.

Non-Metastatic Soft Tissue Sarcoma>2 yearsSafety phase (I)OncologyOrthopedics and Traumatology

Gastrointestinal Stromal Tumors: IDRX-42 Treatment Study

We are testing a new treatment called IDRX-42 for individuals with advanced gastrointestinal stromal tumors that cannot be surgically removed. The study aims to find a safe dosage and assess how well it works against the cancer.

Gastrointestinal Stromal Tumor (GIST)1-2 yearsSafety phase (I)Efficacy phase (II)No Placebo Investigational Medicines Cost Reimbursement Partially RemoteGastroenterologyOncology

Lung Cancer: BMS-986507 Treatment Study

We are testing a new treatment called BMS-986507 for adults with advanced lung cancer to see if it is safe and to find the best dose when used with other therapies.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteOncology

Peripheral T-Cell Lymphoma: New Drug Evaluation

We are testing new drugs for patients with relapsed or refractory peripheral T-cell lymphomas to see if they are safe and improve treatment outcomes. This trial aims to find better options for those who have not responded to existing therapies.

Relapsed or Refractory Peripheral T-Cell Lymphomas>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Rheumatoid Arthritis: CAR-T Therapy vs. Rituximab

We are comparing a new CAR-T cell therapy with rituximab for patients with active rheumatoid arthritis that hasn't responded to other treatments. The goal is to see which therapy is safer and more effective.

Rheumatoid Arthritis1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visits No Placebo Investigational MedicinesRheumatology

Bladder Cancer: Sacituzumab Tirumotecan Study

We are investigating the effects of sacituzumab tirumotecan in individuals with bladder cancer. This study aims to see how well this treatment works compared to standard options.

Intermediate-risk Non-muscle Invasive Bladder Cancer>2 yearsSafety phase (I)Efficacy phase (II)OncologyUrology

Multiple Myeloma: Isatuximab with Novel Agents

We are studying a new combination treatment for people with relapsed or refractory multiple myeloma. This trial aims to find effective doses and evaluate how well these combinations work compared to standard treatments.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Standard MedicinesHematologyOncology

Multiple Myeloma: Isatuximab with Belumosudil and Dexamethasone

We are studying a new combination of treatments for people with relapsed or refractory multiple myeloma. The goal is to find the best dose and see if this combination improves treatment outcomes.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Investigational MedicinesHematologyOncology

Multiple Myeloma: Isatuximab with Evorpacept and Dexamethasone

We are studying a new treatment combination for people with relapsed or refractory multiple myeloma. The goal is to find the best dose and see if it improves treatment responses compared to existing options.